Revlimid OK'd for relapsed/refractory mantle cell lymphoma
This article was originally published in Scrip
Executive Summary
The US FDA on 5 June granted Celgene the OK to market its a thalidomide analogue Revlimid (lenalidomide) as a treatment for patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.